At the Intersection of Science and LawAt the Intersection of Science and Law

Life sciences companies and the risks posed by the mifepristone litigation

View descriptionShare

In this episode, a cross-disciplinary team of FDA regulatory lawyers and life sciences litigators discuss the implications of the mifepristone litigation for life sciences companies as it pertains to citizen petitions, FDA approvals, and strategies manufacturers might consider going forward.

  • Facebook
  • Twitter
  • WhatsApp
  • Email
  • Download

In 1 playlist(s)

  1. At the Intersection of Science and Law

    13 clip(s)

At the Intersection of Science and Law

In DLA Piper’s At the Intersection of Science and Law podcast, members of the firm’s Life Sciences t 
Social links
Follow podcast
Recent clips
Browse 13 clip(s)